Loading…

Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study

The lifetime prevalence of suicide is around 5% in patients with schizophrenia. Non-adherence to antipsychotic medication is an important risk factor, but prospective studies investigating joint effects of antipsychotic drugs, antidepressants, and benzodiazepines on suicidality are scarce. We aimed...

Full description

Saved in:
Bibliographic Details
Published in:Psychological medicine 2024-12, p.1-9
Main Authors: Strømme, Maria Fagerbakke, Thue Augustsson, Mina, Bartz-Johannessen, Christoffer, Stautland, Andrea, Mykletun, Arnstein, Kroken, Rune Andreas, Mehlum, Lars, Kjelby, Eirik, Johnsen, Erik
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c226t-1f07bfdc278ea31d8b1c6d828156d3605643976cf9b4694f17230132464d43413
container_end_page 9
container_issue
container_start_page 1
container_title Psychological medicine
container_volume
creator Strømme, Maria Fagerbakke
Thue Augustsson, Mina
Bartz-Johannessen, Christoffer
Stautland, Andrea
Mykletun, Arnstein
Kroken, Rune Andreas
Mehlum, Lars
Kjelby, Eirik
Johnsen, Erik
description The lifetime prevalence of suicide is around 5% in patients with schizophrenia. Non-adherence to antipsychotic medication is an important risk factor, but prospective studies investigating joint effects of antipsychotic drugs, antidepressants, and benzodiazepines on suicidality are scarce. We aimed to investigate how use and non-use of psychotropic medications are associated with suicidality in schizophrenia. An open cohort study followed all patients consecutively admitted to a psychiatric acute unit during a 10-year period with a diagnosis of schizophrenia ( = 696). Cox multiple regression analyses were conducted with use of antipsychotics, antidepressants, and benzodiazepines as time-dependent variables. Adjustments were made for age, gender, depressive mood, agitated behavior, and use of alcohol and illicit substances. A total of 32 (4.6%) suicide events were registered during follow-up. Of these, 9 (28%) were completed suicides and 23 (72%) were attempted suicides. A total of 59 (8.5%) patients were readmitted with suicidal plans during the follow-up. Compared to non-use, use of antipsychotics was associated with 70% lower risk of attempted or completed suicide (adjusted hazard ratio [AHR] = 0.30, < 0.01, CI 0.14-0.65) and 69% reduced risk of readmission with suicidal plans (AHR = 0.31, < 0.01, CI 0.18-0.55). Use of prescribed benzodiazepines was associated with 126% increased risk of readmission with suicidal plans (AHR = 2.26, = 0.01, CI 1.24-4.13). Adherence to antipsychotic medication is strongly associated with reduced suicidal risk in schizophrenia. The use of prescribed benzodiazepines was identified as a significant risk factor for being readmitted with suicidal plans.
doi_str_mv 10.1017/S0033291724002873
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146607412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146607412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-1f07bfdc278ea31d8b1c6d828156d3605643976cf9b4694f17230132464d43413</originalsourceid><addsrcrecordid>eNplkM1OwzAQhC0EoqXwAFyQj1wCXttxEm6o4k-qxKFwjhzbUVylcYgdUHh6XLVw4bQrzexq5kPoEsgNEMhu14QwRgvIKCeE5hk7QnPgokjyIsuP0XwnJzt9hs683xACDDg9RTNWiBTSHOZosx6tslq2NkxYdhqP3mBX495PqnFhcL1VeGu0VTJY13lsO9zH1XTB4y8bGuxVY79d3wyms_IOS9wPzvdGBftpsHKNGwL2YdTTOTqpZevNxWEu0Pvjw9vyOVm9Pr0s71eJolSEBGqSVbVWNMuNZKDzCpTQOc0hFZoJkgrOikyouqhiVV7H9iwWo1xwzRkHtkDX-78xyMdofCi31ivTtrIzbvRlZCAEyTjQaIW9VcXMfjB12Q92K4epBFLuEJf_EMebq8P7sYpg_i5-mbIfVYR3Dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146607412</pqid></control><display><type>article</type><title>Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study</title><source>Cambridge Journals Online</source><source>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</source><source>Sociology Collection</source><creator>Strømme, Maria Fagerbakke ; Thue Augustsson, Mina ; Bartz-Johannessen, Christoffer ; Stautland, Andrea ; Mykletun, Arnstein ; Kroken, Rune Andreas ; Mehlum, Lars ; Kjelby, Eirik ; Johnsen, Erik</creator><creatorcontrib>Strømme, Maria Fagerbakke ; Thue Augustsson, Mina ; Bartz-Johannessen, Christoffer ; Stautland, Andrea ; Mykletun, Arnstein ; Kroken, Rune Andreas ; Mehlum, Lars ; Kjelby, Eirik ; Johnsen, Erik</creatorcontrib><description>The lifetime prevalence of suicide is around 5% in patients with schizophrenia. Non-adherence to antipsychotic medication is an important risk factor, but prospective studies investigating joint effects of antipsychotic drugs, antidepressants, and benzodiazepines on suicidality are scarce. We aimed to investigate how use and non-use of psychotropic medications are associated with suicidality in schizophrenia. An open cohort study followed all patients consecutively admitted to a psychiatric acute unit during a 10-year period with a diagnosis of schizophrenia ( = 696). Cox multiple regression analyses were conducted with use of antipsychotics, antidepressants, and benzodiazepines as time-dependent variables. Adjustments were made for age, gender, depressive mood, agitated behavior, and use of alcohol and illicit substances. A total of 32 (4.6%) suicide events were registered during follow-up. Of these, 9 (28%) were completed suicides and 23 (72%) were attempted suicides. A total of 59 (8.5%) patients were readmitted with suicidal plans during the follow-up. Compared to non-use, use of antipsychotics was associated with 70% lower risk of attempted or completed suicide (adjusted hazard ratio [AHR] = 0.30, &lt; 0.01, CI 0.14-0.65) and 69% reduced risk of readmission with suicidal plans (AHR = 0.31, &lt; 0.01, CI 0.18-0.55). Use of prescribed benzodiazepines was associated with 126% increased risk of readmission with suicidal plans (AHR = 2.26, = 0.01, CI 1.24-4.13). Adherence to antipsychotic medication is strongly associated with reduced suicidal risk in schizophrenia. The use of prescribed benzodiazepines was identified as a significant risk factor for being readmitted with suicidal plans.</description><identifier>ISSN: 0033-2917</identifier><identifier>ISSN: 1469-8978</identifier><identifier>EISSN: 1469-8978</identifier><identifier>DOI: 10.1017/S0033291724002873</identifier><identifier>PMID: 39651581</identifier><language>eng</language><publisher>England</publisher><ispartof>Psychological medicine, 2024-12, p.1-9</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c226t-1f07bfdc278ea31d8b1c6d828156d3605643976cf9b4694f17230132464d43413</cites><orcidid>0000-0002-5756-1584</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,33612,34531</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39651581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strømme, Maria Fagerbakke</creatorcontrib><creatorcontrib>Thue Augustsson, Mina</creatorcontrib><creatorcontrib>Bartz-Johannessen, Christoffer</creatorcontrib><creatorcontrib>Stautland, Andrea</creatorcontrib><creatorcontrib>Mykletun, Arnstein</creatorcontrib><creatorcontrib>Kroken, Rune Andreas</creatorcontrib><creatorcontrib>Mehlum, Lars</creatorcontrib><creatorcontrib>Kjelby, Eirik</creatorcontrib><creatorcontrib>Johnsen, Erik</creatorcontrib><title>Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study</title><title>Psychological medicine</title><addtitle>Psychol Med</addtitle><description>The lifetime prevalence of suicide is around 5% in patients with schizophrenia. Non-adherence to antipsychotic medication is an important risk factor, but prospective studies investigating joint effects of antipsychotic drugs, antidepressants, and benzodiazepines on suicidality are scarce. We aimed to investigate how use and non-use of psychotropic medications are associated with suicidality in schizophrenia. An open cohort study followed all patients consecutively admitted to a psychiatric acute unit during a 10-year period with a diagnosis of schizophrenia ( = 696). Cox multiple regression analyses were conducted with use of antipsychotics, antidepressants, and benzodiazepines as time-dependent variables. Adjustments were made for age, gender, depressive mood, agitated behavior, and use of alcohol and illicit substances. A total of 32 (4.6%) suicide events were registered during follow-up. Of these, 9 (28%) were completed suicides and 23 (72%) were attempted suicides. A total of 59 (8.5%) patients were readmitted with suicidal plans during the follow-up. Compared to non-use, use of antipsychotics was associated with 70% lower risk of attempted or completed suicide (adjusted hazard ratio [AHR] = 0.30, &lt; 0.01, CI 0.14-0.65) and 69% reduced risk of readmission with suicidal plans (AHR = 0.31, &lt; 0.01, CI 0.18-0.55). Use of prescribed benzodiazepines was associated with 126% increased risk of readmission with suicidal plans (AHR = 2.26, = 0.01, CI 1.24-4.13). Adherence to antipsychotic medication is strongly associated with reduced suicidal risk in schizophrenia. The use of prescribed benzodiazepines was identified as a significant risk factor for being readmitted with suicidal plans.</description><issn>0033-2917</issn><issn>1469-8978</issn><issn>1469-8978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNplkM1OwzAQhC0EoqXwAFyQj1wCXttxEm6o4k-qxKFwjhzbUVylcYgdUHh6XLVw4bQrzexq5kPoEsgNEMhu14QwRgvIKCeE5hk7QnPgokjyIsuP0XwnJzt9hs683xACDDg9RTNWiBTSHOZosx6tslq2NkxYdhqP3mBX495PqnFhcL1VeGu0VTJY13lsO9zH1XTB4y8bGuxVY79d3wyms_IOS9wPzvdGBftpsHKNGwL2YdTTOTqpZevNxWEu0Pvjw9vyOVm9Pr0s71eJolSEBGqSVbVWNMuNZKDzCpTQOc0hFZoJkgrOikyouqhiVV7H9iwWo1xwzRkHtkDX-78xyMdofCi31ivTtrIzbvRlZCAEyTjQaIW9VcXMfjB12Q92K4epBFLuEJf_EMebq8P7sYpg_i5-mbIfVYR3Dw</recordid><startdate>20241209</startdate><enddate>20241209</enddate><creator>Strømme, Maria Fagerbakke</creator><creator>Thue Augustsson, Mina</creator><creator>Bartz-Johannessen, Christoffer</creator><creator>Stautland, Andrea</creator><creator>Mykletun, Arnstein</creator><creator>Kroken, Rune Andreas</creator><creator>Mehlum, Lars</creator><creator>Kjelby, Eirik</creator><creator>Johnsen, Erik</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5756-1584</orcidid></search><sort><creationdate>20241209</creationdate><title>Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study</title><author>Strømme, Maria Fagerbakke ; Thue Augustsson, Mina ; Bartz-Johannessen, Christoffer ; Stautland, Andrea ; Mykletun, Arnstein ; Kroken, Rune Andreas ; Mehlum, Lars ; Kjelby, Eirik ; Johnsen, Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-1f07bfdc278ea31d8b1c6d828156d3605643976cf9b4694f17230132464d43413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strømme, Maria Fagerbakke</creatorcontrib><creatorcontrib>Thue Augustsson, Mina</creatorcontrib><creatorcontrib>Bartz-Johannessen, Christoffer</creatorcontrib><creatorcontrib>Stautland, Andrea</creatorcontrib><creatorcontrib>Mykletun, Arnstein</creatorcontrib><creatorcontrib>Kroken, Rune Andreas</creatorcontrib><creatorcontrib>Mehlum, Lars</creatorcontrib><creatorcontrib>Kjelby, Eirik</creatorcontrib><creatorcontrib>Johnsen, Erik</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychological medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strømme, Maria Fagerbakke</au><au>Thue Augustsson, Mina</au><au>Bartz-Johannessen, Christoffer</au><au>Stautland, Andrea</au><au>Mykletun, Arnstein</au><au>Kroken, Rune Andreas</au><au>Mehlum, Lars</au><au>Kjelby, Eirik</au><au>Johnsen, Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study</atitle><jtitle>Psychological medicine</jtitle><addtitle>Psychol Med</addtitle><date>2024-12-09</date><risdate>2024</risdate><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>0033-2917</issn><issn>1469-8978</issn><eissn>1469-8978</eissn><abstract>The lifetime prevalence of suicide is around 5% in patients with schizophrenia. Non-adherence to antipsychotic medication is an important risk factor, but prospective studies investigating joint effects of antipsychotic drugs, antidepressants, and benzodiazepines on suicidality are scarce. We aimed to investigate how use and non-use of psychotropic medications are associated with suicidality in schizophrenia. An open cohort study followed all patients consecutively admitted to a psychiatric acute unit during a 10-year period with a diagnosis of schizophrenia ( = 696). Cox multiple regression analyses were conducted with use of antipsychotics, antidepressants, and benzodiazepines as time-dependent variables. Adjustments were made for age, gender, depressive mood, agitated behavior, and use of alcohol and illicit substances. A total of 32 (4.6%) suicide events were registered during follow-up. Of these, 9 (28%) were completed suicides and 23 (72%) were attempted suicides. A total of 59 (8.5%) patients were readmitted with suicidal plans during the follow-up. Compared to non-use, use of antipsychotics was associated with 70% lower risk of attempted or completed suicide (adjusted hazard ratio [AHR] = 0.30, &lt; 0.01, CI 0.14-0.65) and 69% reduced risk of readmission with suicidal plans (AHR = 0.31, &lt; 0.01, CI 0.18-0.55). Use of prescribed benzodiazepines was associated with 126% increased risk of readmission with suicidal plans (AHR = 2.26, = 0.01, CI 1.24-4.13). Adherence to antipsychotic medication is strongly associated with reduced suicidal risk in schizophrenia. The use of prescribed benzodiazepines was identified as a significant risk factor for being readmitted with suicidal plans.</abstract><cop>England</cop><pmid>39651581</pmid><doi>10.1017/S0033291724002873</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-5756-1584</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0033-2917
ispartof Psychological medicine, 2024-12, p.1-9
issn 0033-2917
1469-8978
1469-8978
language eng
recordid cdi_proquest_miscellaneous_3146607412
source Cambridge Journals Online; Social Science Premium Collection (Proquest) (PQ_SDU_P3); Sociology Collection
title Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A33%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Suicidality%20and%20use%20of%20psychotropic%20medications%20in%20patients%20with%20schizophrenia:%20a%20prospective%20cohort%20study&rft.jtitle=Psychological%20medicine&rft.au=Str%C3%B8mme,%20Maria%20Fagerbakke&rft.date=2024-12-09&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=0033-2917&rft.eissn=1469-8978&rft_id=info:doi/10.1017/S0033291724002873&rft_dat=%3Cproquest_cross%3E3146607412%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c226t-1f07bfdc278ea31d8b1c6d828156d3605643976cf9b4694f17230132464d43413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3146607412&rft_id=info:pmid/39651581&rfr_iscdi=true